Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects

被引：0

作者：

Roedder, Silke ^{[1
]}

Wendt, Emily ^{[2
]}

Burris, Chad ^{[2
]}

Nazareon, Jonathan ^{[2
]}

Park, Grace ^{[3
]}

Pangilinan, Phil ^{[2
]}

Huang, Gianna ^{[2
]}

Mathur, Anubhav ^{[2
]}

Taylor, James ^{[2
]}

Billin, Andrew ^{[2
]}

Matzkies, Franziska ^{[4
]}

机构：

[1] Gilead Sci, Menlo Pk, CA USA

[2] Gilead Sci, Foster City, CA USA

[3] Gilead Sci, Seattle, WA USA

[4] Gilead Sci Inc, Foster City, CA USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0185

引用

页码：371 / 372

页数：2

共 50 条

[1] POPULATION PHARMACOKINETICS OF GS-5718, AN ORAL INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) INHIBITOR, IN HEALTHY SUBJECTS.
Sathe, A.
Anderson, K.
McFarlane, J.
Othman, A.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S45 - S45
[2] FIRST-IN-HUMAN STUDY OF GS-5718, AN ORAL IRAK-4 INHIBITOR, IN HEALTHY SUBJECTS: PHARMACOKINETICS, SAFETY, TOLERABILITY, AND ASSESSMENT OF EFFECT OF FOOD AND ACID REDUCING AGENTS ON EXPOSURE
Anderson, K.
Hsueh, C. H.
Gurtovaya, O.
Mathur, A.
Taylor, J.
Serone, A.
Othman, A. A.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 581 - 581
[3] The Clinical, Oral Small Molecule IRAK4 Inhibitor, GS-5718, Improves Survival and Reduces Disease Pathologies by Modulating Multiple Inflammatory Endpoints in the Murine NZB/W Model of Spontaneous Lupus
Yadon, Adam
Gorney, Vanessa
Hammond, Angie
Grant, Ethan
Clarke, Astrid
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1097 - 1098
[4] A PHASE-I, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ESCALATING ORAL DOSES OF GS-9620 IN HEALTHY SUBJECTS
Lopatin, U.
Wolfgang, G.
Kimberlin, R.
Tumas, D.
Cornprost, M.
Chittick, G.
Frey, C.
Findlay, J.
Ohmstede, C.
Kearney, B.
Barnes, C.
McHutchinson, J.
Hirsch, K.
JOURNAL OF HEPATOLOGY, 2011, 54 : S296 - S296
[5] First-in-Human Pharmacokinetics and Safety of Escalating Single-and Multiple-Doses of GS-9876, a Novel, Oral SYK Inhibitor, in Healthy Subjects
Dolton, Michael
Matzkies, Franziska
Currie, Kevin
Di Paolo, Julie
Wang, Lu
Zheng, Hao
Ramanathan, Srini
Silverman, Jeffrey
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[6] Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
Zhao, Xia
Sun, Peihong
Zhou, Ying
Liu, Yuwang
Zhang, Huilin
Mueck, Wolfgang
Kubitza, Dagmar
Bauer, Richard J.
Zhang, Hong
Cui, Yimin
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (01) : 77 - 88
[7] Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects
Vandell, Alexander G.
Inoue, Satoshi
Dennie, Justin
Nagasawa, Yasuo
Gajee, Roohi
Pav, Joe
Zhang, George
Zamora, Cynthia
Masuda, Nobuhisa
Senaldi, Giorgio
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (05)
[8] FIRST-INHUMAN STUDY OF SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF IRAK1/4 INHIBITOR R835 IN HEALTHY SUBJECTS
Yan, L.
Tong, S.
Absalom, A.
Daas, I. D.
Park, G.
Taylor, V.
Chow, D.
Lee, M.
Zheng, H.
Chow, A.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 332 - 332
[9] Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study
Jin, Byung Hak
Hong, Taegon
Yoo, Byung Won
Kim, Choon Ok
Kim, Dasohm
Kim, Youn Nam
Park, Min Soo
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (10):
[10] A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of DS-3801b, a Motilin Receptor Agonist, in Healthy Subjects
Dennie, Justin
Atiee, George
Warren, Vance
Tao, Ben
Morimoto, Kiyoshi
Senaldi, Giorgio
JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (09): : 1221 - 1230

← 1 2 3 4 5 →